Clinical trials: Ticagrelor
Coronary Artery Disease
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Numerous studies have shown that pharmacodynamics (PD) response profiles vary among clopidogrel treated patients and that individuals with reduced response have an increased risk of recurrent ischemic events.
- Trial name
- NCT02065479
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
Cerebral Infarction, Stroke
In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease
This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients.
- Conditions
- Cerebral Infarction, Stroke, Nervous System Diseases, Ischemic Cerebrovascular Disease
- Trial name
- NCT05716646
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
Coronary Artery Disease, Myocardial Ischemia
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
A real world registry to compare dual therapy with Dabigatran/Ticagrelor to dual therapie with Dabigatran/Clopidogrel in patients with an indication for NOAC undergoing PCI in the setting of ACS.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Atrial Fibrillation
- Trial name
- RE-DUAL PCI (NCT04688723)
- Testing
- Dabigatran + Ticagrelor, Dabigatran + clopidogrel
- Where
- Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Zuyderland Medisch Centrum
Healthy Subjects
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- TIC-025-23 (NCT06233266)
- Testing
- Ticagrelor-Test product, Ticagrelor-Reference product
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Stent Thrombosis, Myocardial Infarction, Acute
TADCLOT- a Double Blind Randomized Controlled Trial
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
- Trial name
- TADCLOT (NCT06318481)
- Testing
- Ticagrelor 90 MG, Clopidogrel
- Where
- Pakistan
- Volunteers
- 2,200 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Myocardial Injury
Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery
The purpose of this pilot study is to establish the rate of cardiovascular events in patients with elevated troponins levels after major, non-cardiac surgery and to evaluate the efficacy and safety of FDA approved study drug…
- Trial name
- INTREPID (NCT02291419)
- Testing
- ticagrelor, aspirin
- Where
- 24 sites in United States
- Volunteers
- 6 people
- Sponsor
- The Cleveland Clinic
Stroke, Ischemic Attack, Transient
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition…
- Trial name
- PRINCE (NCT02506140)
- Testing
- Ticagrelor and Acetylsalicylic acid, Clopidogrel and Acetylsalicylic acid
- Where
- 25 sites in China
- Volunteers
- 675 people
- Sponsor
- Beijing Tiantan Hospital
Stable Chronic Angina
Ticagrelor vs. Clopidogrel in Post PCI Patients
Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg…
- Trial name
- NCT05858918
- Testing
- Clopidogrel, Ticagrelor
- Where
- Iran
- Volunteers
- 476 people
- Sponsor
- Shiraz University of Medical Sciences
Acute Coronary Syndrome
Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor
Antiplatelet therapy with ticagrelor is currently indicated for treatment of patients presenting with acute coronary syndrome. Such therapy is started with the administration of a loading dose in patients which are not yet under…
- Trial name
- SHIFT-OVER (NCT01795820)
- Testing
- loading with Ticagrelor, no loading with Ticagrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University Magna Graecia
Acute Coronary Syndrome (ACS)
OPTImal Management of Antithrombotic Agents: OPTIMA-5
This is a prospective, randomized, open-label clinical trial which will enroll 80 acute coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI) in China.
- Trial name
- NCT04116931
- Testing
- Switch ticagrelor to clopidogrel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Coronary Syndrome
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
East Asian patients will be required optimal dose of newer P2Y12 inhibitors (prasugrel or ticagrelor) to determine the safer treatment and better outcome.
- Trial name
- NCT02944123
- Testing
- Clopidogrel 75 mg, Prasugrel 5 mg, Ticagrelor 45 mg
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Dong-A University
Coronary Artery Disease
Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor
The administration of Ticagrelor have demonstrated superiority to Clopidogrel in patients presenting with acute coronary syndrome (ACS) and remains a first line therapy as an adjunct to aspirin for patients admitted with ACS.
- Trial name
- CABG-TIME (NCT02627521)
- Testing
- PRU guided CABG, CABG per standard of care, VerifyNow assay
- Where
- Canada
- Volunteers
- 260 people
- Sponsor
- Unity Health Toronto
Myocardial Infarction
Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor
The current trial will compare the protective effect of ticagrelor and prasugrel on microvascular dysfunction in patients with revascularized ST elevation myocardial infarction.
- Trial name
- REDUCE-MVI (NCT02422888)
- Testing
- Ticagrelor, Prasugrel
- Where
- Netherlands
- Volunteers
- 110 people
- Sponsor
- Amsterdam UMC, location VUmc
Blood Flow Speed, Coronary Flow Velocity
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.
- Trial name
- NCT01226602
- Testing
- AZD6140
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers
The purpose of this study is to assess the pharmacokinetics of AZD6140 and its active metabolite, safety, tolerability of AZD6140 following single administration in healthy male Japanese volunteers.
- Trial name
- NCT01588626
- Testing
- AZD6140
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD).
- Trial name
- NCT03381755
- Testing
- half-dose ticagrelor, standard-dose ticagrelor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Acute Coronary Syndrome, Platelet Function
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
Introduction: Platelet aggregation plays an important role in ischemic complications in patients undergoing to percutaneous coronary intervention (PCI).
- Trial name
- SAMPA (NCT02215993)
- Testing
- Prasugrel, Ticagrelor
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Acute Coronary Syndrome
Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome
This study will try to determine if the measure of the platelet reactivity of the patients receiving from the ticagrelor continuation in an acute coronary syndrome handled by coronary angioplasty allows to predict the hemorrhagic…
- Trial name
- NCT02428725
- Testing
- blood sample
- Where
- France
- Volunteers
- 640 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Novel Oral Anticoagulants, NOACs
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Individual differences in drug efficacy and adverse reactions are common in the clinical application of drugs. Individual differences are caused by many factors, among which genetic factors account for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT05764356
- Testing
- Detection of genotype and RNA profile in platelet and white blood cell, Indicators test related to coagulation function, Indicators test related to platelet function
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Peking University First Hospital
Coronary Artery Disease, Ticagrelor
The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
The study is to further exploring the optimal switching strategy by evaluating the pharmacodynamic responses as well as adverse events in patients with complexity of coronary artery disease managed by percutaneous coronary…
- Trial name
- NCT03577652
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shenyang Northern Hospital